Table 1.
The correlation between PRPS2 expression and clinicopathological characteristics was analyzed in prostate cancer by IHC (n = 78).
| Variables | Total N | PRPS2 | χ2 | p valueb | |
|---|---|---|---|---|---|
| High expression (++/+++, n, %) |
Low expression (-/+, n, %) |
||||
| Type | |||||
| Normal/BPH | 16 | 7 (43.8) | 9 (56.3) | 5.608 | 0.018 |
| PCa | 78 | 60 (76.9) | 18 (23.1) | ||
| Age(years) | |||||
| ≤ 66a | 39 | 26 (66.77) | 13 (33.3) | 0.692 | 0.406 |
| > 66 | 55 | 41 (74.5) | 14 (25.5) | ||
| Clinical stage | |||||
| I- II | 42 | 28 (66.7) | 14 (33.3) | 5.114 | 0.024 |
| III- IV | 35 | 31 (88.6) | 4 (11.4) | ||
| Primary tumor | |||||
| T1-T2 | 41 | 27 (65.0) | 14 (34.1) | 5.966 | 0.015 |
| T3-T4 | 37 | 33 (89.2) | 4 (10.8) | ||
| Gleason Score | |||||
| ≤7 | 31 | 23 (74.2) | 8 (25.8) | 0.265 | 0.607 |
| ≥8 | 48 | 38 (79.2) | 10 (20.8) | ||
Notes: a, mean age. b, p value is from χ2-test -test. ‑/+, total expression score 0‑3; ++/+++, total expression score 4‑9. Abbreviations: PCa, prostate cancer.